
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx Inc. has shown a notable increase in revenue, reporting $422K in Q2, up from $197K in Q1, indicating a positive upward trend for the company. Forecasts suggest strong revenue growth potential, with expectations of reaching $1.3 million in 2025 and $4.5 million in 2026. As a clinical-stage biopharmaceutical company, RenovoRx is addressing high unmet medical needs in cancer treatment, which bolsters the outlook for future financial performance driven by its innovative therapies.
Bears say
RenovoRx Inc reported revenue of $0.4 million alongside a net loss of $2.9 million, resulting in an earnings per share (EPS) of $(0.08), which aligned with consensus estimates but highlights the ongoing financial vulnerability of the company. The company's focus on developing therapies for pancreatic cancer faces significant challenges, given the disease's bleak 5-year overall survival rate of just 12%, potentially limiting market adoption and revenue generation. Additionally, while there are prospects for growth within the biopharmaceutical sector, the inherent risks associated with clinical-stage companies such as RenovoRx raise concerns about future financial stability and investor confidence.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares